RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000129.xml
Kardiologie up2date 2010; 6(4): 283-287
DOI: 10.1055/s-0030-1255990
DOI: 10.1055/s-0030-1255990
Hotline – Koronare Herzerkrankung und Atherosklerose
© Georg Thieme Verlag KG Stuttgart · New York
Statine in der Primärprävention der koronaren Herzkrankheit
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
13. Januar 2011 (online)
![](https://www.thieme-connect.de/media/kardiologie-u2d/201004/lookinside/thumbnails/10.1055-s-0030-1255990-1.jpg)
Abstract
Besides its potent LDL-cholesterol lowering effect, statins have proven to be beneficial in secondary prevention of myocardial infarction, reduce stroke, and also total mortality. Although the evidence of a beneficial role in secondary prevention is unequivocal, their role in primary prevention is still discussed controversially.
Literatur
- 1 Libby P, Crea F. Clinical Implications of inflammation for cardiovascular primary prevention. Eur Heart J. 2010; 31 777-783
- 2 The Emerging Risk Factors Collaboration . C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010; 375 132-140
- 3 Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109 39-43
- 4 Shepherd J, Cobbe S M, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333 1301-1307
- 5 Downs J R, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279 1615-1622
- 6 Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006; 368 1155-1163
- 7 Ridker P M, Danielson E, Fonseca F A et al. Rosuvastatin to prevent events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359 2195-2207
- 8 Koenig W, Ridker P M. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5 % or Framingham risk > 20 %: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J. 2010; [Epub ahead of print]
- 9 Genest J, McPherson R, Frohlich J et al. 2009 Canadian cardiovascular society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendation. Can J Cardiol. 2009; 25 567-579
- 10 Brugts J J, Yetgin T, Hoeks S E et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ. 2009; 338 b2376
Prof. Dr. Wolfgang Koenig
Universitätsklinikum Ulm
Zentrum für Innere Medizin
Klinik für Innere Medizin II
Albert-Einstein-Allee 23
89081 Ulm
eMail: wolfgang.koenig@uniklinik-ulm.de